All Releases
 |
BioCryst to Present at Two Upcoming Investor Conferences
May 9, 2013
|
11.6 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives
from BioCryst are scheduled to present and provide a corporate
summary and update regarding the Company's clinical programs at the
following investor conferences:
...
|
|
BioCryst Provides Corporate Update and Reports First Quarter 2013 Financial Results
May 7, 2013
|
22.0 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial
results for the first quarter ended March 31, 2013.
"We are pleased that our recent interactions with the FDA have defined a
pathway to file a peramivir
NDA for ...
|
|
BioCryst to Announce First Quarter 2013 Financial Results May 7
Apr 23, 2013
|
12.4 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first
quarter 2013 financial results will be released on Tuesday, May 7, 2013.
BioCryst will host a conference call and webcast at 11:00 a.m. Eastern
Time to discuss the financial results...
|
|
BioCryst Pharmaceuticals Completes Peramivir Type C Meeting
Apr 16, 2013
|
13.4 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has
completed its Type C meeting regarding intravenous (i.v.) peramivir
with the U.S. Food & Drug Administration (FDA) and has received final
meeting minutes. The minutes of the meeting we...
|
|
BioCryst Pharmaceuticals Provides Update Regarding Peramivir
Apr 1, 2013
|
15.0 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it received
a preliminary comment letter from the U.S. Food & Drug Administration
(FDA) that outlines a pathway by which BioCryst could file a New Drug
Application (NDA) seeking regulatory ap...
|
|
BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4161 for the Treatment of Hereditary Angioedema
Mar 25, 2013
|
15.1 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the initiation
of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and
pharmacodynamics of orally-administered BCX4161
in healthy volunteers. Discovered by BioCryst, BCX4161 is a ...
|
|
BioCryst Reports Fourth Quarter and Full Year 2012 Financial Results
Feb 19, 2013
|
24.8 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial
results for the fourth quarter and full year ended December 31, 2012.
"Our team is focused on achieving near-term milestones to rebuild
shareholder value. Our primary goa...
|
|
BioCryst to Announce Fourth Quarter & 2012 Financial Results on February 19, 2013
Feb 5, 2013
|
12.4 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its fourth
quarter and full year 2012 financial results will be released on
Tuesday, February 19, 2013. BioCryst will host a conference call and
webcast at 11:00 a.m. Eastern Time to discuss ...
|
|
BioCryst to Present at J.P. Morgan Healthcare Conference
Jan 2, 2013
|
9.2 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that Jon
Stonehouse, President and Chief Executive Officer of BioCryst is
scheduled to present and provide a corporate summary and update
regarding the Company at the 31st annual J.P. Morgan
...
|
|
BioCryst Pharmaceuticals Announces Focused Corporate Strategy and Restructuring
Dec 7, 2012
|
16.6 KB |
| |
2013 cash utilization projected to drop 38-45% versus 2012
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that in response
to recent events and an assessment of its assets, the Company is
restructuring and implementing a ...
|
|
BioCryst Pharmaceuticals and Presidio Pharmaceuticals Mutually Terminate Merger Transaction
Nov 30, 2012
|
12.2 KB |
| |
RESEARCH TRIANGLE PARK, N.C. & SAN FRANCISCO--(BUSINESS WIRE)--
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and privately held Presidio
Pharmaceuticals, Inc. today announced the mutual termination of the
Merger Agreement and the related Investor Financing Agreement entered
into on October 17, 2012. Although the ...
|
|
BioCryst Broad-Spectrum Antiviral BCX4430 Highly Effective against Yellow Fever in a Preclinical Disease Model
Nov 12, 2012
|
13.8 KB |
| |
Results to be presented at the 2nd
Antiviral Congress today
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced
proof-of-principle data demonstrating that BCX4430 is efficacious and
well tolerated in a preclinical dis...
|
|
BioCryst Provides Corporate Update and Reports Third Quarter 2012 Financial Results
Nov 8, 2012
|
33.6 KB |
| |
Third quarter 2012 results call now scheduled November 8 at 8:30
a.m. ET
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial
results for the third quarter and nine months ended September 30, 2012.
...
|
|
BioCryst Announces Outcome from the Peramivir Phase 3 Interim Analysis
Nov 7, 2012
|
15.8 KB |
| |
BioCryst management to discuss outcome during its third quarter
2012 results call now scheduled November 8 at 8:30 a.m. ET
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced completion of
the planned interim analysis of the p...
|
|
BioCryst to Report Third Quarter 2012 Financial Results on November 8, 2012
Nov 1, 2012
|
12.7 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its third
quarter 2012 financial results will be released on Thursday, November 8,
2012. BioCryst will host a conference call and webcast at 11:00 a.m.
Eastern Time to discuss the financial r...
|
|
BioCryst Provides Update Regarding BCX5191 Development Plan Following Discussion With FDA
Oct 30, 2012
|
18.1 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the withdrawal
of its Investigational New Drug application (IND) for the antiviral
nucleoside, BCX5191,
following a discussion with the U.S. Food and Drug Administration (FDA).
...
|
|
BioCryst Pharmaceuticals and Presidio Pharmaceuticals to Merge
Oct 18, 2012
|
23.0 KB |
| |
New company to focus on oral drugs for hepatitis C and hereditary
angioedema
Combined HCV portfolio includes three complementary viral
targeting mechanisms
RESEARCH TRIANGLE PARK, N.C. & SAN FRANCISCO--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ...
|
|
BioCryst Provides Corporate Update and Reports Second Quarter 2012 Financial Results
Aug 2, 2012
|
27.2 KB |
| |
Hepatitis C and hereditary angioedema programs advancing into
clinical trials
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial
results for the second quarter and six months ended June 30, 2012.
...
|
|
BioCryst Announces Positive Results from Two Ulodesine Phase 2 Trials in Patients with Gout
Jul 24, 2012
|
20.2 KB |
| |
Confirmation of favorable ulodesine
safety profile through 52 weeks
Proportion of patients reaching serum uric acid goal sustained
at 52 weeks
Management to discuss during conference call/webcast August 2,
2012 at 11 a.m. ET
...
|
|
BioCryst to Report Second Quarter 2012 Financial Results on August 2, 2012
Jul 19, 2012
|
12.8 KB |
| |
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its second
quarter 2012 financial results will be released on Thursday, August 2,
2012. BioCryst will host a conference call and webcast at 11:00 a.m.
Eastern Time to discuss the financial re...
|
|
|
